Tilanus-Linthorst, M., Geuzinge, A., Obdeijn, I., Rutgers, E., Mann, R., Saadatmand, S., de Roy van Zuidewijn, D., Oosterwijk, J., Tollenaar, R., Ausems, M., van 't Riet, M., Margrethe, S., Hooning, M., Wesseling, J., Kristine, K., Luiten, E., Verhoef, C., Heijnsdijk, E., & de Koning, H. (2021). faMRIsc trial shows: MRI breast screening for women with ≥20% lifetime risk is also cost-effective in Europe. European journal of surgical oncology, 47(2), e19–. http://access.bl.uk/ark:/81055/vdc_100160119346.0x00003c